Equity · Healthcare
CYTK
NASDAQCytokinetics, Incorporated
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for CYTK to draw a line in its place.
as of Jul 24, 2026
CYTK insider trades
Showing the 12 most recent of 17 open-market trades in this window. The figures above count all of them.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 14 compensation filings in this window. The figures above count all of them.
CYTK reported financials
SEC EDGARCYTK reported revenue of $88.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$785.0M.
CYTK earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
CYTK institutional holders
SEC EDGAR12 of the 45 institutional funds we track reported a CYTK position for the quarter ended 30 Jun 2026 — a combined $519.1M; the latest of those filings landed 02 Sep 2026.
Showing the 10 largest of 12 reported positions. The figures above count all of them.
CYTK fails-to-deliver
SECOn 30 Sep 2026, 2,845 shares of CYTK failed to deliver (about $187K).
Congressional trades in CYTK
House disclosuresThe most recent congressional trade disclosed in CYTK is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 29 Sep 2026.
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARValuation computed from SEC EDGAR filings